Quest Diagnostics (DGX) risk factors
Item 1A of every Quest Diagnostics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors34 risks1 new4 dropped13 reworded
The company added a specific risk regarding data privacy controls compliance. Regulatory updates highlight the invalidation of the FDA laboratory-developed test rule. Reimbursement pressures from Medicare and PAMA implementation flaws remain prominent.
Filed Feb 26, 2026 - FY2024 10-K risk factors37 risks
Quest Diagnostics faces significant risks from evolving value-based reimbursement models and government and third-party payer pricing pressures. The company carries $6.2 billion in debt and operates in a highly competitive, regulated clinical testing market. Cybersecurity threats, AI adoption challenges, and labor constraints among specialized personnel threaten operations.
Filed Feb 20, 2025